Jason Efstathiou, Vice President at Radiation Oncology Institute (ROI) – The ASTRO Foundation, shared a post on X:
“Great to be at the GU Bladder SS08 session at ASTRO25, diving into some of the most important questions in bladder cancer today. This session is highlighting emerging biomarkers that may guide treatment decisions (such as ctDNA), as well as whether treating pelvic lymph nodes is necessary in this disease. With three compelling abstracts on the table, the discussion underscores just how much progress is being made in refining and personalizing care for bladder cancer patients.
Sessions like this remind us of the power of research to challenge assumptions and shape the future of practice.”
More from Jason Efstathiou on OncoDaily.